
Product Data Sheet

Product Name: Ibiglustat succinate

Cat. No.: GC68163

Chemical Properties

Cas. No. 1629063-80-4

Formula C₂₄H₃₀FN₃O₆S

M.Wt 507.57

Solubility DMSO : ≥ 250 mg/mL (492.54 mM)

Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant **glucosylceramide synthase (GCS)** inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease^{[1][2]}.

Ibiglustat (SAR402671) succinate (1 μM, 15 days; Fabry disease (FD) cells) is close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat succinate can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes^[4].

[1]. Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. *Sci Rep.* 2021;11(1):20945. Published 2021 Oct 22.

[2]. Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. *Clin Pharmacol Drug Dev.* 2021;10(1):86-98.

[3]. Iva Stojkowska, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. *Cell Tissue Res.* 2017.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

[4]. Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014;37(6):1013-1022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA